Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program.
Robbins HA, Alcala K, Moez EK, Guida F, Thomas S, Zahed H, Warkentin MT, Smith-Byrne K, Brhane Y, Muller D, Feng X, Albanes D, Aldrich MC, Arslan AA, Bassett J, Berg CD, Cai Q, Chen C, Davies MPA, Diergaarde B, Field JK, Freedman ND, Huang WY, Johansson M, Jones M, Koh WP, Lam S, Lan Q, Langhammer A, Liao LM, Liu G, Malekzadeh R, Milne RL, Montuenga LM, Rohan T, Sesso HD, Severi G, Sheikh M, Sinha R, Shu XO, Stevens VL, Tammemägi MC, Tinker LF, Visvanathan K, Wang Y, Wang R, Weinstein SJ, White E, Wilson D, Yuan JM, Zhang X, Zheng W, Amos CI, Brennan P, Johansson M, Hung RJ.
Robbins HA, et al. Among authors: warkentin mt.
Ann Epidemiol. 2023 Jan;77:1-12. doi: 10.1016/j.annepidem.2022.10.014. Epub 2022 Oct 29.
Ann Epidemiol. 2023.
PMID: 36404465
Free PMC article.